Recent Updates
Recently added Catalysts

Rivastigmine prevention of delirium

Phase 3

Delirium | Small Molecules | Psychiatry |Novartis AG|Trials Updated: Jul 31, 2007

Rivastigmine prevention of delirium development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Nov 2005

Rivastigmine prevention of delirium target and mechanism

Molecular targetBCHE, ACHE
Target classInhibitor
ModalitySmall Molecules
ChEMBLCHEMBL636

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment120

FDA Designations

No designations recorded

Rivastigmine prevention of delirium clinical trials

Rivastigmine prevention of delirium · 1 trial · 1 indication

Phase 3 1
NCT00257868Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac SurgeryDelirium
COMPLETED120 Analytics
PHASE3COMPLETED
Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery
DeliriumUnlock trial analytics

Study Endpoints

Primary Endpoints

Development of postoperative delirium within 7 days after cardiac surgery

Secondary Endpoints

Severity of delirium occurring within 7 days after cardiac surgery
Length of stay (intensive care and hospital)
Amount of drugs used for rescue therapy of delirium
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
Rivastigmine prevention of deliriumDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range65 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients undergoing cardiac surgery with use of extracorporeal circulation * Aged 65 or more Exclusion Criteria: * "redo" procedures * anticipated use of succinylcholine during operation * contraindications to rivastigmine * preoperative mini mental score \< 15

Countries:Switzerland
Unlock Eligibility Criteria

Frequently asked questions about Rivastigmine prevention of delirium

What is rivastigmine used for in delirium?

Rivastigmine is being studied for the prevention of delirium, specifically postoperative delirium in patients undergoing cardiac surgery. The Phase 3 trial NCT00257868 evaluated rivastigmine for this use in patients aged 65 years and older in Switzerland. It is not approved for delirium prevention.

How does rivastigmine work?

Rivastigmine is a small molecule inhibitor of the enzymes acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE). By inhibiting these enzymes, it reduces the breakdown of acetylcholine, which may help maintain cholinergic signaling. This mechanism is being investigated for the prevention of delirium.

Who is developing rivastigmine for delirium prevention?

Novartis AG (ticker: NVS) is the developer of rivastigmine for the prevention of delirium. The company sponsored the Phase 3 trial evaluating this use.

What phase is rivastigmine for delirium prevention in?

Rivastigmine for the prevention of delirium is in Phase 3 development. The single Phase 3 trial, NCT00257868, has been completed. The drug is investigational for this indication and has not been approved for delirium prevention.

What clinical trials is rivastigmine in for delirium?

One clinical trial has evaluated rivastigmine for delirium: NCT00257868, titled "Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery." This completed Phase 3 trial enrolled 120 patients aged 65 years and older in Switzerland. It was randomized and double-blind.